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Rosana Herna´ndez, MD, PHD,* Carlos Macaya, MD, PHD*
Madrid, Spain
Objectives The aim of this study was to compare the efficacy and safety of drug-eluting stent (DES) and bare-metal stent
(BMS) use in chronic total occlusion (CTO) recanalization.
Background The long-term effectiveness and safety of DES use in CTO recanalization are unclear, and performance of ran-
domized clinical trials in the field is complex.
Methods Major electronic information sources were explored for articles comparing outcomes with DES and BMS use
among patients with CTO. Assessed clinical outcomes were death, myocardial infarction, target vessel revascu-
larization, major adverse cardiac events, and stent thrombosis; angiographic outcomes were stent restenosis
and stent reocclusion.
Results Fourteen comparative studies were identified (a total of 4,394 patients). When compared with BMS, DES signifi-
cantly reduced risk of major adverse cardiac events (relative risk [RR]: 0.45, 95% confidence interval [CI]: 0.34
to 0.60, p  0.001) and TVR (RR: 0.40, 95% CI: 0.28 to 0.58, p  0.001) without increasing death (RR: 0.87,
95% CI: 0.66 to 1.16, p  0.88) or myocardial infarction (RR: 0.89, 95% CI: 0.54 to 1.46, p  0.80). This bene-
fit was sustained at 3 years of follow-up. Lower RRs for restenosis (RR: 0.25, 95% CI: 0.16 to 0.41, p  0.001)
and stent reocclusion (RR: 0.30, 95% CI: 0.18 to 0.49, p  0.001) were also observed in the DES group. A
strong trend toward a higher rate of stent thrombosis was documented in DES-treated patients (RR: 2.79, 95%
CI: 0.98 to 7.97, p  0.06).
Conclusions DES use in CTO recanalization is associated with significantly fewer major adverse cardiac events and fewer oc-
currences of target vessel revascularization, restenosis, and stent reocclusion than with BMS. Although a statisti-
cal trend toward a higher risk of stent thrombosis was observed, the use of DES in this context seems to be
safe, with an overall benefit sustained in the long term. (J Am Coll Cardiol 2010;55:1854–66) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.038t
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Recanalization of chronic total occlusion (CTO) is one of
he most challenging percutaneous coronary interventions
PCI). Procedural success is hampered by the difficulties
ssociated with crossing the occluded segment with guide-
ires and recanalization devices, and long-term results are
hreatened by a high restenosis rate (1). The introduction of
rug-eluting stents (DES), which have been demonstrated
o cause less restenosis than bare-metal stents (BMS) in
pecific patient and stenosis subsets, has raised hopes of
mproving long-term vessel patency after CTO recanaliza-
rom the *Cardiovascular Institute and †Preventive Medicine Unit, Hospital Clı´nico
an Carlos, Madrid, Spain.d
Manuscript received September 16, 2009; revised manuscript received November
3, 2009; accepted December 17, 2009.ion (2). However, limited evidence of the benefit and safety
f DES use in CTO is available, partly due to inherent
ifficulties in conducting dedicated randomized clinical
rials (RCTs) in this field. To shed further light on this
ssue, we performed a systematic review and meta-analysis at
he study level of existing RCTs and non-RCTs reporting
utcomes of DES versus BMS use in patients with CTO.
ethods
tudy objectives and clinical definitions. The aim of this
ystematic review and meta-analysis was to compare out-
omes of DES and BMS for the treatment of CTO in
CTs and non-RCTs. Clinical outcomes of interest were
eath, myocardial infarction (MI), target vessel revasculariza-
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April 27, 2010:1854–66 DES in CTOion (TVR), stent thrombosis (ST), and major adverse
ardiac events (MACE). Angiographic outcomes were stent
estenosis and reocclusion. Definitions of the end points
sed in the studies were contrasted with the standardized
efinitions proposed by Cutlip et al. (3) for coronary stent
rials. If end points fell outside these standardized defini-
ions, those used by the original authors are specified.
tudy search strategy. A bibliographic search covering the
eriod January 2002 to May 2009 was conducted indepen-
ently by 2 investigators, first in MEDLINE and Cochrane
ibrary databases, and then in conference proceedings of
he Scientific Sessions of the American College of Cardio-
ogy, American Heart Association, European Society of
ardiology, Transcatheter Cardiovascular Therapeutics, and
uroPCR as well as their websites. Appropriate free text and
arious permutations of the MeSH terms “stent” or “drug-
luting stent” or “bare-metal stent” and coronary total
cclusion or “comparative study” were used in the search.
o language restrictions were applied.
tudy selection. Identified studies were reviewed and se-
ected if they reported a direct comparison of DES (siroli-
us or paclitaxel) and BMS in CTO recanalization and
ncluded clinical or angiographic outcome data at 6-
onth follow-up after stent implantation.
Inclusion or exclusion of studies was performed hierar-
hically based on the title of the report first, followed by the
bstract, and then by the full text. If the initial study was
ollowed by a more complete study or studies that included
he original dataset, the most recent and complete report
as chosen. Such linked studies were identified on the
rounds of authorship, institutions, design, length of
ollow-up, and study populations. Disagreement on study
election was resolved by consulting a third investigator.
tudy classification. Studies were classified according to
he Cochrane Intervention Meta-analysis Handbook into 4
ategories (4): 1) nonrandomized, controlled trials (CTO
atients were nonrandomly allocated to DES or BMS
reatment); 2) retrospective cohort studies (patients with
TO treated with DES or BMS were retrospectively
dentified and long-term outcomes were assessed); 3) his-
orically controlled trials (outcome of patients with CTO
reated with DES were compared with a nonconcurrent
roup treated with BMS); and 4) RCTs (CTO patients
ere randomly allocated to DES or BMS treatment). We
efer generically to categories 1, 2, and 3 as nonrandomized
omparative studies (NRCS).
ata extraction and assessment of quality. Two investi-
ators independently assessed appropriate treatment alloca-
ion and adequacy of analysis in each study. Extracted data
ncluded first author, publication year, study design,
linical and angiographic characteristics, type of interven-
ion (number of patients allocated to BMS or DES
mplantation), stent type, length of follow-up, and out-
omes of interest. The quality of studies was scored using
he Cochrane Collaborations tool for assessing risk of
ias for RCTs (4) and the Newcastle-Ottawa scale for cRCS (5). Discrepancies were
esolved by discussion with a
hird investigator.
tatistical analysis. Interob-
erver agreement was performed
sing Cohen’s weighted kappa.
he relative risk (RR) for each
tudy outcome was calculated
rom abstracted data using the
nverse variance method. Statis-
ical heterogeneity was assessed
sing Cochrane’s Q via the chi-
quare test and further quantified
ith the I2 test. The number
eeded to treat (NNT) was cal-
ulated to depict the clinical ef-
ect of treatment. Overall treat-
ent effect was first calculated
eparately for RCTs and NRCS
nd then for pooled data. To be
onservative, a random-effects
odel was used. Whenever I2
as 50% and p  0.1, bivariate
eta-regressions were performed
o investigate the potential sources
f heterogeneity. This included
egressions of the log RR on clinical and methodological
ariables. Sensitivity analysis for each outcome was per-
ormed; a 20% modification of the overall effect by
xclusion of a given study was considered significant. Strat-
fied analysis was performed to assess the effect of study
uality and clinical factors. Weighted regression analysis
as performed to investigate the relationship between
aseline patient risk and treatment benefit. Publication bias
as assessed using funnel plots, Begg’s correlation, and
gger’s regression. In assessing heterogeneity, p  0.1 was
onsidered statistically significant; otherwise, p  0.05 was
sed to indicate significance. Analyses were performed using
eview Manager Version 5.1 (Cochrane Collaboration,
oftware Update, Oxford, United Kingdom) and Epidat
ersion 3.1 (Xunta de Galicia/Panamerican Health Organi-
ation WHO).
esults
iterature search. Figure 1 shows the QUORUM flow
hart, providing a description of publication screening and
easons for exclusion. Agreement between investigators
egarding data search was good (kappa  0.89). Fourteen
tudies (2 RCTs and 12 NRCS) were finally selected for
ata extraction (6–19). The authors of 2 conference pro-
eedings were contacted, and they provided additional
nformation on their studies (14,15).
uality assessment. Agreement between reviewers on
uality assessment was good in NRCS (kappa  0.85), and
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CTO  chronic total
occlusion
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event
MI  myocardial infarction
NNT  number needed to
treat
NRCS  nonrandomized
comparative study/studies
PCI  percutaneous
coronary intervention
RCT  randomized clinical
trial
RR  relative risk
RRR  relative risk
reduction
ST  stent thrombosis
TVR  target vessel
revascularizationomplete in RCTs (kappa  1.00). Table 1 summarizes
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DES in CTO April 27, 2010:1854–66uality ratings for included studies. Both RCTs scored as
oderate quality: the first RCT had an open, single-blind
esign, whereas the second was a post hoc subgroup analysis
rom the SCANDSTENT trial (10). The quality of NRCS
anged from moderate (4 of 8 stars) to good (7 of 8 stars).
djustment techniques using a propensity score or match-
ng were performed in 4 (33%) NRCS.
haracteristics of the studies and patients included.
greement between investigators regarding data extraction
as good (kappa 0.85). The meta-analysis included 4,394
atients (2,004 with BMS, 2,390 with DES). Table 2
ummarizes number, demographic, clinical, and angio-
raphic characteristics of patients. One of the studies with a
istorically controlled study design (19) used as a BMS
ontrol group patients previously included in an RCT,
hich compared balloon angioplasty with BMS for the
reatment of CTO (20). Angiographic characteristics and
linical outcomes of the PRISON II trial were extracted
rom separate studies (11,21). Overall, the clinical charac-
    MEDLINE search (n= 612)
    COCHRANE Library databases  (n= 35)
    Abstracts of conference proceeding  (n=33)
     Website search (n=18)
Review of abstracts (n= 295)
Review of full text (n= 25)
Articles included in systematic review (n= 14)
12 non-randomized studies
2 randomized trials 
Citations potentially eligible (n= 751)
Figure 1 Study Selection Flow Diagram
The selection algorithm applied in selecting of comparative studies for the meta-analyeristics of patients allocated to DES and BMS treatment (ere comparable. The prevalence of diabetes ranged from
4% to 33%; in 1 study (15), the prevalence of diabetes was
ignificantly higher in the DES arm. The proportion of
revious MI ranged from 35% (9) to 73% (17). The mean
eference vessel diameter ranged from 2.60 mm (9) to 3.61
m (19) and occlusion length from 16 mm (12) to 32.5 mm
9). In 4 studies, occlusion and stent lengths were signifi-
antly longer in the DES group (6,7,17,19).
Table 1 shows main study characteristics. Eight studies were
istorically controlled studies, 3 were retrospective cohort
tudies, 2 were RCTs, and 1 was an NRCS. Most patients had
n average duration of occlusion 12 weeks (4,044 of 4,394
atients, 10 of 14 studies). The mean angiographic follow-up
as 6 months, and clinical follow-up ranged from 6 to 60
onths (mean 22 months). Eight studies used sirolimus-
luting stents, 2 studies used paclitaxel-eluting stents, and 4
tudies used both sirolimus- and paclitaxel-eluting stents. The
inimum duration of dual antiplatelet therapy (aspirin plus
lopidogrel) ranged from 3 (sirolimus-eluting stents) to 6
Exclusion based on title (n=456)
  Different interventions (n=134)
New devices in CTO (n=49)
      Technique descriptions in CTO (n=33)
  Review articles (n=25)
Case reports (n=17)
Guidelines (n=9)
Non-comparative trials (n=4)
Trials comparing different DES in CTO (n=6)
Duplicate information (n=4)
Poor quality assessment  (n=1)
Exclusion based on abstracts content (n=270)
Exclusion based on full text (n=11)
Exclusion based on title (n=456)
hown schematically. CTO  chronic total occlusion; DES  drug-eluting stent(s).sis is spaclitaxel-eluting stents) months.
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April 27, 2010:1854–66 DES in CTOTable 3 provides complementary information regarding
he angiographic and clinical benefit of DES use expressed
s RR, relative risk reduction (RRR), NNT, and the p value
f each study as well as its impact on overall population.
ACE. All studies reported MACE incidence. Nine re-
orted a significant MACE reduction associated with DES
se (Table 3). The MACE in the study by Kandzari et al.
19) were not entered in the meta-analysis because the
efinition of MI applied in its control group (21) was
eemed substantially different from that of the remaining
tudies. Pooled analysis of the remaining 13 studies (n 
,992) revealed 803 MACE (20.11%): per treatment, the
ACE rate was 13.51% (296 of 2,190) in the DES group
nd 28.13% (507 of 1,802) in the BMS group. The overall
R was 0.45 (95% confidence interval [CI]: 0.34 to 0.60,
 0.001) and the RRR was 53% (Fig. 2). The NNT for
DES to prevent 1 TVR event was 9 patients (95% CI: 8
o 11). Significant heterogeneity was detected across studies,
haracteristics and Quality Assessment of the Studies IncludedTable 1 Characteristics and Quality Assessment of the Studies
First Author
(Ref. #)
Angiographic
Follow-Up (Months),
% of Patients
Clinical
Follow-Up
(Months) Design
Kim et al. (6) 6, 68% BMS/67% DES 6 HCT
Ge et al. (7) 6, 80% BMS/67% DES 7 HCT
Nakamura
et al. (8)
6, 75% BMS/75% DES 12 NRCT
Migliorini
et al. (9)
6, 81% BMS/80% DES 6 HCT
Kelbæk et al.
(10)
7, 95% BMS/89% DES 17 RCT, open-design
Suttorp et al.
(11)
6, 100% BMS/100% DES 36 RCT, single-blind
Werner et al.
(12)
6, BMS: NA/DES: N/A 36 HCT
Garcı´a-Garcı´a
et al. (13)
36, BMS: NA/50% DES 36 HCT
Aleksiadi
et al. (14)
6, 100% BMS/100% DES 6 RCS
Obunai et al.
(15)
6, 40% BMS/40% DES 36 RCS
La Spina et al.
(16)
— 26* RCS
De Felice
et al. (17)
— 18 HCT
Han et al. (18) — 60† RCS
Kandzari et al.
(19)‡
6, 85% BMS/85% DES 12 HCT
Mean follow-up was 26 months. †Clinical follow-up was up to 5 years. ‡Bare-metal stent data wer
core: selection (S) (maximum 3 diamonds), comparability (C) (maximum 2 diamonds), outcome
BMS bare-metal stent(s); DES drug-eluting stent(s); HCT historically controlled trial; ISR
umen diameter; NA  not available; NRCT  nonrandomized, controlled trial; PES  paclitaxel-el
D  stenosis diameter; SES  sirolimus-eluting stent; ST  stent thrombosis; TVF  target vessnd meta-regression analysis identified design type (  r3.50, p 0.001) and stent length (1.99, p 0.004)
s main determinants. Sensitivity analysis yielded an RR
ange of 0.46 (95% CI: 0.33 to 0.65) to 0.54 (95% CI: 0.43
o 0.68), and exclusion of individual studies did not signif-
cantly modify the overall effect.
The relationship between MACE reduction associated
ith DES use and the baseline risk characteristics of the
atients included in the studies was explored. Baseline risk
as defined as the MACE rate in the BMS group.
eighted regression analysis demonstrated a direct and
ignificant relationship between baseline risk of MACE and
enefit in terms of MACE reduction associated with DES
se (p  0.001) (Fig. 3). Stratified analysis by follow-up
ength demonstrated a sustained benefit in MACE reduc-
ion 3 years after recanalization with DES (RR: 0.53, 95%
I: 0.38 to 0.74, p  0.001) (Fig. 4).
VR. A total of 4,206 patients were included in 13 studies
eporting TVR rates (2 RCTs and 11 NRCS). Ten studies
uded
nterventions
1/Primary End Point,
2/Secondary End Point
Quality Assessment
(0 to 8 Diamonds)
vs. SES or PES 1/MACE and TVR RR S:, C:, O: (4/8)
vs. SES 1/MACE and RR S:, C:, O: (6/8)
vs. SES 1/MACE, 2/RR S:, C:, O: (7/8)
vs. SES or PES 1/MACE, 2/RR and
reocclusion
S:, C:, O: (7/8)
vs. BMS 1/MLD different at FU,
2/TVF, MACE, RR,
and SD
Allocation sequence: yes;
allocation concealed: yes;
blinding: no;
complete outcome data: yes;
full reporting: yes
vs. BMS 1/restenosis rate,
2/MACE, TVF, SD,
and late loss
Allocation sequence: yes;
allocation concealed: yes;
blinding: single;
complete outcome data: yes;
full reporting: yes
vs. PES 1/MACE, 2/RR and
reocclusion
S:, C:, O: (7/8)
vs. SES 1/MACE, 2/TVR and MI S:, C:, O: (6/8)
vs. SES 1/Binary restenosis,
2/MACE
S:, C:, O: (6/8)
vs. SES or PES 1/MACE, 2/RR and ST S:, C:, O: (7/8)
vs. SES or PES 1/MACE, 2/TVR, ST S:, C:, O: (6/8)
vs. SES or PES 1/MACE, 2/TVR S:, C:, O: (6/8)
vs. SES or PES 1/MACE, 2/ISR S:, C:, O: (6/8)
vs. SES RR; late loss, failure of
sustained patency,
and MACE
S:, C: , O: (7/8)
ded from the TOSCA (Total Occlusion Study of Canada) trial. Newcastle Ottawa Scale study quality
ximum 3 diamonds).
t restenosis; MACEmajor adverse cardiac event; MImyocardial infarction; MLDminimum
ent; RCS  retrospective cohort study; RCT  randomized, controlled trial; RR  restenosis rate;
re; TVR  target vessel revascularization.Incl
I
BMS
BMS
BMS
BMS
SES
SES
BMS
BMS
BMS
BMS
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DES in CTO April 27, 2010:1854–66Table 3). Figure 2 includes data on TVR in both treatment
roups. Pooled data analysis revealed 741 TVR events
overall rate 16.86%). Regarding stent type, TVR occurred
n 11.71% (275 of 2,347) of DES-treated patients and
3.95% (466 of 1,945) of BMS-treated patients. The overall
R was 0.41 (95% CI: 0.29 to 0.58, p  0.001), yielding a
9% risk reduction in TVR with DES use. The number
eeded to treat with a DES to prevent 1 TVR event was
0 patients (95% CI: 9 to 12). The overall effect was
omparable between RCTs and NRCS. Stratified analy-
is by length of follow-up revealed that DES use was
ssociated with a significant benefit 3 years after inter-
ention (RR: 0.52, 95% CI: 0.36 to 0.75, p  0.001) (Fig.
). Substantial heterogeneity, which was found across stud-
es, was related to study design type (3.21, p 0.02),
tent length (  0.01, p  0.001) and the percentage of
atients with angiographic follow-up (  0.009, p 
.004). Sensitivity analysis showed an RR range from 0.27
95% CI: 0.21 to 0.50) to 0.36 (95% CI: 0.15 to 0.49), and
linical and Angiographic Characteristics of Patients in the IncludeTable 2 Clinical and Angiographic Characteristics of Patients i
Characteristics
Kim et al. (6) (2004)* Ge et al. (7
BMS
(n  79)
DES
(n  115)
BMS
(n  259)
n 194 38
Mean age, yrs NA NA 61 10
Male, % NA NA 87
Diabetes, % NA NA 19
HTA, % NA NA 43
Previous MI, % NA NA 63
MVD, % NA NA 70
LVEF, % NA NA 53 11
RVD, mm 3.03 0.48 2.92 0.25 2.7 0.6
MLD post 2.89 0.57 2.69 0.47 2.6 0.5
Lesion length 25.76 13.1 33.66 19.65‡ 9.6 6.90
Stent length (mm) NA NA 21.7 9.2
DO, weeks 12 1
Garcı´a-Garcı´a et al. (13) (2007) Aleskiadi et al.
BMS
(n  71)
DES
(n  76)
BMS
(n  60)
n 147 10
Mean age, yrs 61 11 61 11 58
Male, % 77 66 NA
Diabetes, % 6 15 21
HTA, % 36 42 31
Previous MI, % 51 51 NA
MVD, % NA NA NA
LVEF, % NA NA NA
RVD, mm NA NA NA
MLD post NA NA 2.01 0.42
Lesion length NA NA 13.6 3.9
Stent length 21.7 6.3 22.50 6.1 NA
DO, weeks 12 1
Year in parentheses is the year of publication. †Values expressed as LVEF 50% (% of patients).
edian (quartile 1, quartile 3) or n (%) in the DES group.
DO duration of occlusion; HTA hypertension; LVEF left ventricular ejection fraction; MLD postm
iameter; other abbreviations as in Table 1.xclusion of individual studies did not significantly modify
he overall effect.
As similarly performed for MACE, the relationship
etween TVR reduction associated with DES use and
aseline risk of TVR in the BMS group in the studies
ncluded was investigated. A direct and significant relation-
hip between these indices was found in the weighted
egression analysis (p  0.001) (Fig. 3).
I. MI rates were reported in 11 studies (2 RCTs and 9
RCS) including 2,701 patients; 70 events were reported
Table 3). The MI events documented in the study by
andzari et al. (19) were not entered in the meta-analysis on
he grounds previously described for MACE. The MI
ncidence was 1.95% (29 of 1,483) in the DES group and
.36% (41 of 1,218) in the BMS group. Figure 5 shows the
Rs of MI in randomized and nonrandomized studies.
here were no statistically significant differences between
he BMS and DES groups. The overall RR was 0.96 (95%
I: 0.56 to 1.57, p  0.82). There was no evidence of
alsIncluded Trials
5) Nakamura et al. (8) (2005) Migliorini et al. (9) (2006)
DES
122)
BMS
(n  120)
DES
(n  60)
BMS
(n  26)
DES
(n  92)
180 131
 10 69 8 70 9 64 10 67 11
88 63 70 NA NA
28 33 33 19 18
50 60 58 16 51
55 35 37 46 51
79 84 78 41 41
 10 56 7 52 8 NA NA
 0.4 3.32 0.5 3.12 0.6 2.6 0.6 2.6 0.5
 0.4 3.12 0.48 3.04 0.5 2.6 0.3 2.7 0.4
 10.2 32.5 7.8 35 8.8 33 24 39 22
 19.5§ 30.8 8.8 36.5 2.2 40 19 51 28
12 12
2007) Obunai et al. (15) (2008) La Spina et al. (16) (2009)
DES
 47)
BMS
(n  270)
DES
(n  560)
BMS
(n  23)
DES
(n  88)
830 111
62 11 62 11 64 10 64 10
89 87 82 87
20 30§ 30 29
NA NA 65 62
63 48§ NA NA
77 73 NA NA
54 10 52 10 NA NA
NA NA NA NA
 0.24 2.82 0.56 2.60 0.55§ NA NA
 4.1 20.9 15.6 25.9 17.4§ NA NA
NA 30.32 23.65 46.39 23.16§ 31 16.5 31 17
12 12
.05. §p  0.001. No available data for each group. ¶Baseline characteristics were expressed asd Trin the
) (200
(n 
1
61
53
2.8
2.6
10.4
41.6
2
(14) (
(n
7
8
2.32
14.2
2
‡p  0inimum lumen diameter post-stenting (mm); MVDmultivessel disease; RVD reference vessel
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April 27, 2010:1854–66 DES in CTOtatistical heterogeneity between studies (p heterogeneity 
.91). Sensitivity analysis did not reveal significant changes
n the overall RR associated with exclusion of individual
tudies.
eath. Thirteen studies (2 RCTs and 11 NRCS) involving
total of 4,287 patients, reported the incidence of death in
hose allocated to BMS (n  1,944) or DES (n  2,343)
reatment (Table 3). There were a total of 186 deaths. The
ncidence of death was 4.09% (96 of 2,343) in the DES
roup and 4.62% (90 of 1,944) in the BMS group. There
as no statistically significant difference in the occurrence of
eath among the studies. One exception was the study by
erner et al. (12), which found a statistically borderline
ecrease (p  0.05) in the death rate associated with DES
se. The overall RR was 0.87 (95% CI: 0.66 to 1.16, p 
.88). Figure 5 shows the number of deaths documented in
oth treatment groups for both randomized and nonran-
omized studies. No heterogeneity among studies was
etected (I2  0%, p  0.73), and sensitivity analysis did
ontinuedTable 2 Continued
Kelbæk et al. (10) (2006) Suttorp et
BMS
(n  63)
DES
(n  64)
BMS
(n  100)
127
61 9 64 10 59 10
81 77 76
21 19 16
33 48 46
55 64 51
38 39 49
51 10 51 11 50 (82)†
2.91 0.5 2.92 0.48 2.60 0.65
2.46 0.51 2.44 0.44 1.96 0.47
22.8 10 27.5 15 16.3 9.3
28.1 12.4 35.3 18.7 28.9 13.7
12
De Felice et al. (17) (2009) Han et al. (
BMS
(n  112)
DES
(n  111)
BMS
(n  524)
223 1,1
62 10 63 11 58 12
77 75 83
31 31 21
71 70 54
73 61 52
47 51 80
50 10 52 9 NA
2.98 0.47 2.87 0.38 NA
2.5 0.4 2.41 0.3 NA
16.7 6.9 23.7 9.6§ NA
21.8 8.4 37 15.2 37 11.1
4ot reveal significant changes in the overall RR associated
ith exclusion of individual studies.
estenosis. Figure 6 shows the forest plot of the RR of
estenosis in 10 studies (8 NRCS and 2 RCTs, n 
,635) reporting angiographic restenosis rates (Table 3).
ollow-up coronary angiography was performed in 1,967
75%) patients, revealing restenosis in 464 (106 in the
ES group and 358 in the BMS group). The restenosis
ate was significantly decreased by DES use: 10.65% in
he DES group and 36.83% in the BMS group (RR: 0.25,
5% CI: 0.16 to 0.41, p  0.001). The overall RR was
omparable between RCTs and NRCS. The NNT with
ES use was 5 patients (95% CI: 4 to 6). Significant
eterogeneity was documented for both RCTs and
RCS, with study design as the main determinant ( 
0.47, p  0.04). Sensitivity analysis, which revealed RR
hifts from 0.32 (95% CI: 0.21 to 0.50) to 0.40 (95% CI:
.27 to 0.61), found no significant influence of individual
tudies on the overall effect.
1) (2006) Werner et al. (12) (2007)*
DES
(n  100)
BMS
(n  95)
DES
(n  95)
190
60 11 64 10 63 10
83 74 78
10 28 31
45 76 83
47 49 38
53 NA NA
50 (76)† 64 19 62 17
2.53 0.67 2.63 0.57 2.55 0.46
2.01 0.51 2.16 0.6 2.26 0.36
16 9.3 22 13 23 16
31.9 15.3 35 18 42 21‡
12
009) Kandzari et al. (19) (2009)¶
DES
(n  660)
BMS
(n  202)
DES
(n  200)
402
59 12 58 11 60 (55, 67)§
82 84 80
23 15 25§
51 35 70§
54 67 34
78 NA NA
NA 60 11 —
NA 3.61 0.57 2.93 (2.5, 3.3)§
NA 2.45 0.59 2.32 0.30
NA NA NA
37.9 11.7 28 15.4 49.6 (33, 65)§
12al. (1
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12
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DES in CTO April 27, 2010:1854–66tent reocclusion. Figure 6 shows a separate analysis for
tent reocclusion, recorded in 6 NRCS and 1 RCT (n 
,475). Stent reocclusion occurred in 103 patients treated
ith DES (n  673) or BMS (n  802) and was
ignificantly lower in DES-treated patients: 2.97% in the
ES-treated patients and 10.35% in BMS-treated patients
RR: 0.30, 95% CI: 0.18 to 0.49, p  0.001) (Table 3).
ikewise, in the RCT by Suttorp et al. (11), stent reocclu-
ion occurred in 4% of patients treated with a DES (n 
00) and in 13% of patients treated with a BMS (n  100).
he overall RR estimated for this trial is similar to that of
onrandomized studies. An NNT of 14 (95% CI: 12 to 20)
as calculated for DES use. Heterogeneity across studies
as not detected (I2  0%, p  0.57). Sensitivity analysis
linical and Angiographic Clinical Benefit of Drug-Eluting Stent Useomp red With Bare Metal Stent Use in Chronic Total OcclusionTable 3 Clin cal and Angiographic Clinical Benefi of Dr g-ElutiCompared With Bare Metal Stent Use in Chronic Total
Kim
et al. (6)
Ge
et al. (7)
Nakamura
et al. (8)
MACE events 10/2 91/20 50/2
BMS/DES
RR, 95% CI 0.14 (0.03–0.61) 0.47 (0.30–0.72) 0.08 (0.02–0.
RRR, % 86 53 99
NNT, 95% CI 9 (5–33) 5 (4–10) 3 (2–4)
p value 0.01 0.001 0.001
TVR events 10/1 75/21 44/2
BMS/DES
RR, 95% CI 0.07 (0.01–0.53) 0.31 (0.17–0.56) 0.09 (0.02–0.
RRR, % 99 69 99
NNT, 95% CI 8 (5–23) 5 (4–8) 3 (2–4)
p value 0.01 0.001 0.001
MI events 0/0 20/10 3/7
BMS/DES
RR, 95% CI Not estimable 1.06 (0.51–2.20) 1.13 (0.29–4.
RRR, % NE NE NE
NNT, 95% CI NE NE NE
p value Not estimable 0.87 0.72
Death events 0/1 3/3 0/0
BMS/DES
RR, 95% CI 2.07 (0.09–50.1) 2.12 (0.43–10.3) Not estimab
RRR, % NE NE NE
NNT, 95% CI NE NE NE
p value 0.85 0.35 Not estimab
Restenosis events 16/1 76/11 38/1
BMS/DES
RR, 95% CI 0.05 (0.01–0.34) 0.30 (0.17–0.53) 0.05 (0.01–0.
RRR, % 95 70 95
NNT, 95% CI 5 (4–10) 4 (3–8) 3 (3–5)
p value 0.003 0.001 0.001
Stent reocclusion events NA 15/3 7/1
BMS/DES
RR, 95% CI NA 0.42 (0.13–1.44) 0.29 (0.04–2.
RRR, % NA NE NE
NNT, 95% CI NA NE NE
p value NA 0.17 0.23ielded an RR ranging from 0.41 (95% CI: 0.28 to 0.61) to a.56 (95% CI: 0.27 to 0.76), showing no significant influ-
nce of individual studies on the overall effect.
T. Figure 7 shows the forest plot for ST. Of the 7 studies
n  2,261) recording ST, 4 (7,12,13,19) used protocol ST
efinitions and 3 (15,16,20) used Academic Research Con-
ortium ST criteria (3). There were 45 (1.99%) occurrences
f ST, including 25 possible ST events classified by Aca-
emic Research Consortium criteria. Excluding possible ST
ases, the incidence of ST was 1.28% (16/1,241) in the DES
roup and 0.39% (4/1,020) in the BMS group. The corre-
ponding RR was 2.79 (95% CI: 0.98 to 7.97, p  0.1). In
he DES group, there were 4 early and 5 late ST events.
nly 3 studies reported ST occurring after the first year
15,16,20). Very late ST occurred in 7 DES-treated patients
ent Use
usion
Study
Migliorini
et al. (9)
Kelbæk
et al. (10)
Suttorp
et al. (11)
Werner
et al. (12)
6/9 22/3 20/4 53/18
0.42 (0.17–1.08) 0.13 (0.04–0.43) 0.20 (0.07–0.56) 0.34 (0.22–0.53)
58 87 80 66
2 (2–3) 3 (2–6) 6 (4–14) 3 (2–4)
0.07 0.001 0.01 0.001
6/7 21/3 22/8 49/14
0.30 (0.11–0.83) 0.14 (0.04–0.45) 0.36 (0.17–0.78) 0.29 (0.17–0.48)
70 88 64 31
6 (3–63) 2 (1–3) 6 (14–15) 3 (2–4)
0.04 0.001 0.01 0.001
0/0 1/0 6/5 4/0
Not estimable 0.33 (0.01–7.91) 0.83 (0.26–2.64) 0.11 (0.01–2.04)
NE NE NE NE
NE NE NE NE
Not estimable 0.99 1 0.16
0/2 0/0 4/4 8/0
1.45 (0.07–29.3) Not estimable 1 (0.26–0.3.89) 0.29 (0.00–1.00)
NE NE NE NE
NE NE NE NE
0.94 Not estimable 1 0.05
10/15 38/0 41/11 55/9
0.43 (0.23–0.86) 0.01 (0.00–0.19) 0.27 (0.15–0.49) 0.16 (0.09–0.31)
57 99 73 82
5 (2–50) 2 (1–3) 3 (2–5) 2 (2–4)
0.05 0.001 0.001 0.001
5/9 NA 13/4 22/1
0.49 (0.18–1.33) NA 0.31 (0.10–0.91) 0.05 (0.01–0.33)
NE NA 69 99
NE NA 11 (6–71) 5 (3–7)
0.21 NA 0.004 0.001
Continuedng St
Occl
32)
61)
32)
le
le
37)
27)nd no BMS-treated patients (p  0.07). There was no
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p
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April 27, 2010:1854–66 DES in CTOvidence of statistical heterogeneity among trials (I2  0%,
 0.88).
ublications bias. Visual inspection of the funnel plot for
estenosis, stent reocclusion, and MACE did not reveal
symmetry. In support of this finding, Begg’s rank correla-
ion and Egger’s regression test results were not statistically
ignificant. Although asymmetry was observed on visual
ontinuedTable 3 Continued
Garcia-Garcia
et al. (13)
Aleskiadi
et al. (14)
Obunai
et al. (15
MACE events 13/12 10/1 55/71
BMS/DES
RR, 95% CI 0.86 (0.42–1.76) 0.07 (0.01–0.53) 0.62 (0.45–0
RRR, % NE 93 38
NNT, 95% CI NE 8 (5–23) 13 (8–45)
p value 0.71 0.87 0.01
TVR events 9/7 NA 48/58
BMS/DES
RR, 95% CI 0.73 (0.29–1.85) NA 0.58 (0.41–0
RRR, % NE NA 42
NNT, 95% CI NE NA 13 (8–45)
p value 0.33 NA 0.006
MI events 2/2 NA 3/7
BMS/DES
RR, 95% CI 0.93 (0.14–6.46) 1.01 (0.06–15.93) 1.01 (0.06–15
RRR, % NE NA NE
NNT, 95% CI NE NA NE
p value 0.94 NA 0.86
Death events 4/5 NA 6/10
BMS/DES
RR, 95% CI 1.17 (0.33–4.18) NA 0.80 (0.30–2
RRR, % NE NA NE
NNT, 95% CI NE NA NE
p value 0.81 NA 0.67
Restenosis events NA 13/2 49/39
BMS/DES
RR, 95% CI NA 0.20 (0.05–0.83) 0.40 (0.28–0
RRR, % NA 80 60
NNT, 95% CI NA 5 (3–18) 20 (11–83
p value NA 0.03 0.001
Stent reocclusion events NA NA NA
BMS/DES
RR, 95% CI NA NA NA
RRR, % NA NA NA
NNT, 95% CI NA NA NA
p value NA NA NA
Overall MACE TVR
Events 539/316 466/275 4
BMS/DES
RR, 95% CI 0.45 (0.34–0.60) 0.41 (0.29–0.58) 0.89 (0
RRR, % 55 59
NNT, 95% CI 9 (8–11) 10 (9–12)
p value p  0.001 p  0.001 0
A  not assessed; NE  not effective; NNT  number needed to treat to prevent 1 event; RR nspection of the funnel plot for TVR, Begg’s rank corre- aation and Egger’s regression test results were not statisti-
ally significant (p  0.11 and p  0.06, respectively).
iscussion
his systematic review and meta-analysis reveal that, when
ompared with BMS use, the use of DES in CTO recan-
La Spina
et al. (16)
De Felice
et al. (17)
Han
et al. (18)
Kandzari
et al. (19)
6/19 13/12 149/121 NA
0.83 (0.37–1.83) 0.36 (0.42–0.74) 0.64 (0.52–0.80) NA
NE 64 34 NA
NE 7 (4–20) 10 (7–21) NA
0.72 0.009 0.001 NA
4/12 22/5 139/128 17/19
0.78 (0.28–2.21) 0.23 (0.09–0.58) 0.73 (0.59–0.90) 1.13 (0.60–2.11)
NE 67 27 NE
NE 7 (4–15) 15 (9–56) NE
0.68 0.002 0.01 0.71
1/4 1/1 NA NA
1.05 (0.12–8.91) 1.01 (0.06–15.93) NA NA
NE NE NA NA
NE NE NA NA
0.94 0.99 NA NA
1/4 2/3 51/64 1/0
1.05 (0.12–8.91) 1.51 (0.26–8.88) 0.83 (0.60–1.16) 0.34 (0.01–8.21)
NE NE NE NE
NE NE NE NE
0.94 0.64 0.98 0.79
NA NA NA 27/21
NA NA NA 0.78 (0.46–1.33)
NA NA NA 22
NA NA NA NE
NA NA NA 0.39
NA NA NA 21/5
NA NA NA 0.24 (0.09–0.63)
NA NA NA 64
NA NA NA 13 (8–31)
NA NA NA 0.004
Death Restenosis
Stent
Reocclusion
90/96 358/106 83/23
.46) 0.87 (0.66–1.16) 0.25 (0.16–0.41) 0.30 (0.18–0.49)
NE 75 70
NE 5 (4–6) 14 (12–20)
0.88 p  0.001 p  0.001
risk; RRR  risk relative reduction; other abbreviations as in Tables 1 and 2.)
.86)
.83)
.93)
.19)
.58)
)
MI
1/29
.54–1
NE
NE
.80lization is associated with significantly fewer MACE and
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DES in CTO April 27, 2010:1854–66VR occurrences and significantly less restenosis and stent
eocclusion. The benefit of using DES in terms of MACE
nd TVR reduction seems to be proportional to baseline risk
nd remains at 3 years of follow-up. Finally, a strong
rend toward a higher stent thrombosis rate was docu-
ented in DES-treated patients.
Over the past years, CTO recanalization has received
uch attention as one of the major frontiers of PCIs, and
dvisory documents highlighting technical and organiza-
ional aspects have been published (22,23). Some peculiar-
ties of stenting in CTO that deserve attention are the
bsolute absence of endothelial cells and the exposure of
eep plaque components at the site of stenting, the almost
nvariable presence of well-developed coronary collaterals,
nd the frequent need to stent long coronary segments.
ome of these issues were proposed during the BMS era to
xplain the high restenosis rates associated with stent
mplantation in CTO (24). Some of these features may
emain unfavorable in the DES era in terms of achieving
trut endothelialization and coverage by neointima, an issue
f major concern regarding late ST (25). RCTs of CTO
ecanalization are difficult to conduct due to the large
Historically-controlled studies
De Felice et al                         6.8 
Garcia-Garcia et al         6.9  
Ge et al          9.6  
Kandzari et al          9.3  
Kim et al          2.4  
Migliorini et al          6.4  
Wemer et al          10.2 
Subtotal RR: 0.38 [0.22,0.66] 51.6 
Heterogeneity:  I2 = 68%; (P = 0.004);
P < 0.001) 
Retrospective cohort studies
HAN et al          12.6
La Spina et al          16.2 
Obunai et al          11.6 
Subtotal RR: 0.69 [0.58,0.83] 30.4 
Heterogeneity: I2 = 0% ; (P = 0.54) 
Non-Randomized controlled studies
Nakamura et al         4.4  
Subtotal RR: 0.09 [0.02,0.36] 4.4 
Heterogeneity: Not applicable 
P < 0.001) 
Randomized control trials
Rahel and Suttorp et al         8.2 
Kelbæk et al          5.4  
Subtotal RR:  0.25 [0.10,0.62] 13.6 
Heterogeneity:  I2 = 45%; (P = 0.18)
Overall RR:  0.41 [0.29,0.58] 100
Heterogeneity:  I2 = 73%; (P < 0.001); 
 Study or subgroup                                              RR (Random),95% CI         Weight (%)
Favors DES                       Favors BMS 
 0.001         0.1             1            10           100
        Major adverse cardiac events  
Figure 2 RR of a MACE and Target Vessel Revascularization A
Forest plots for relative risk (RR) of major adverse cardiac events and target vesse
use. Studies are grouped according to study design. RR for each outcome is show
monds), and pooled data (overall RR, blue diamonds and blue dotted lines), show
RR calculation is given in a separate column.umber of patients required, slow patient recruitment, belatively low success rate (80%) in crossing the CTO, and
he limited number of experienced operators. Meta-analysis
onstitutes, therefore, a valuable tool to explore this issue,
roviding not only statistical evidence of the efficacy and
afety of DES use in CTO recanalization, but also allowing
uantification of outcomes to a point on which other an-
lyses, such as cost-effectiveness, can be built upon.
The benefit of using DES to ensure long-term success of
TO is confirmed by this meta-analysis. A clear superiority
f the DES over the BMS in decreasing MACE was
ocumented, with an associated 55% RRR, despite the
nclusion of 3 studies failing to demonstrate a decrease in
ACE associated with DES use (9,14,16). This superiority
as mainly due to a reduction in the TVR rate, without
ignificant differences in death or MI rate. Although 3
omparative studies reported neutral results in terms of
VR reduction with BMS or DES use (13,16,19), this
eta-analysis provides conclusive evidence that DES use
ecreases the occurrence of TVR after CTO recanalization,
ith a 59% RRR: 1 repeat revascularization was avoided by
reating 10 CTO patients with a DES. Stratified analysis
evealed that the benefit associated with DES persists
Historically-controlled studies
De Felice et al          7.1  
Garcia-Garcia et al         7.1  
Ge et al                       11.4  
Kim et al          3.0
Migliorini et al          5.9 
Werner et al                       11.2  
Subtotal RR:  0.66 [0.31,0.59] 47.4 
Heterogeneity: I2 = 34%; (P = 0.17)  
Retrospective cohort studies
Aleksiadi et al           5.3  
HAN et al          14.2 
La Spina et al           7.2  
Obunai et al          13.9 
Subtotal RR: 0.66 [0.55,0.78] 39.6  
Heterogeneity: I2 = 0%; (P = 0.70)
Non-randomlzed controlled studies 
Nakamura et al         3.4  
Subtotal RR: 0.08 [0.02,0.32] 3.4  
Heterogeneity: Not applicable 
Randomized control trials
Rahel and Suttorp et al         5.2
Kelbæk et al          4.4  
Subtotal RR:  RR: 0.17 [0.08,0.36] 9.6 
Heterogeneity:  I2 = 0%; (P = 0.61)
Overall RR: 0.45 [0.34,0.60] 100 
Heterogeneity: I2 = 62%; (P = 0.001) 
Favors DES                       Favors BMS 
 0.001         0.1             1            10           100
tudy or subgroup                                              RR (Random),95% CI         Weight (%)
            Target vessel revascularization 
ated With DES and BMS Use
scularization associated with drug-eluting stent (DES) or bare-metal stent (BMS)
ndividual studies (red squares), study design subgroups (subtotal RR, gray dia-
% confidence intervals (CI). Individual and grouped study weights used in overall S
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April 27, 2010:1854–66 DES in CTOegression analysis demonstrated that the benefit of DES use in
erms of reducing TVR, restenosis, and MACE is related to
he likelihood of long-term occurrence of TVR in the corre-
ponding BMS-treated patients. This finding is consistent
ith other studies in non-CTO lesions that documented
reater benefit of DES use over BMS use in patients at higher
isk of events after revascularization (26).
It is interesting to note that the observed 11.71% TVR
ate associated with DES is virtually identical to that
0    .1          .2                   .3            .4                    .5
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BMS MACE rate (%)
 y = 0.11 - 0.01 X
r =  0.85
p < 0.001
   MAJOR ADVERSE CARDIAC EVENTS   
Figure 3 Relationship Between Outcome Rates in the BMS Arm
Weighted regression of baseline risk (defined as target vessel revascularization ra
BMS arms for TVR and a major adverse cardiac event (MACE) in the included stud
Abbreviations as in Figure 2.
Studies with follow-up < 3 years 
Aleksiadi et al                         4.8  
De Felice et al               7.7  
Ge et al                             12  
Kelbæk et al                            10.4 
Kim et al                2.7
Migliorini et al               5.5  
Nakamura et al                3   
Subtotal RR:  0.42 [0.27,0.65]                   46.1  
 
Studies with follow-up  ≥ 3 years
Garcia-Garcia et al                             7.7  
HAN et al                15.9  
Obunai et al                 14  
Rahel and Suttorp et al               4.7  
Werner et al                 11.6  
Subtotal RR:  0.53 [0.38,0.74]                                                        53.9  
 
Overall RR:   0.48 [0.37,0.62]                                           100
 Study or subgroup                                           RR (Random),95% CI        Weight (%)
Favors DES                       Favors BMS 
    0.01         0.1             1            10           100
     MACE by length of follow-up  
Figure 4 RR of a MACE and TVR Associated With DES and BM
Forest plots for RR risk of TVR and MACE rates stratified by length of follow-up (
Same graph layout and color coding as in Figure 2. Abbreviations as in Figures 2 aeported by other authors in other off-label DES indications
27). Because TVR is a clinical end point, driven mainly by
he reappearance of angina, the similarity with non-CTO
atients treated with DES might seem paradoxical, given
hat occluded vessels usually have more collateral support
hat might attenuate or even abolish anginal symptoms.
otential explanations include the reported regression of
ollateral support after CTO recanalization (28) and the
nclusion of a significant number of studies performing
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BMS TVR rate (%)
 y = 0.06 - 0.01 X
r =  0.87
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                                 TARGET VESSEL REVASCULARIZATION 
the Risk Difference Between DES and BMS Use
] in the BMS group) and DES benefit (defined as risk difference in DES and
negative risk difference indicates an advantage for DES compared with BMS.
Studies with follow-up < 3 years 
De Felice et al                7.4  
Ge et al                10.1  
Kandzari et al                10.1  
Kelbæk et al                         6.0  
Kim et al                2.8  
Migliorini et al               6.9  
Nakamura et al               4.8 
Subtotal RR:  0.26 [0.12,0.56]    ]        48.1 
Studies with follow-up  ≥ 3 years
Garcia-Garcia et al              7.4  
HAN et al               12.9  
Obunai et al              12.1   
Rahel and Suttorp et al             8.7  
Werner et al              10.7  
Subtotal RR:  0.52 [0.36,0.75]                     51.9 
  
Overall RR: 0.39 [0.27,0.57]                                            100
 
 Study or subgroup                                           RR (Random),95% CI      Weight (%)
Favors DES                       Favors BMS 
    0.01         0.1             1            10           100
                    TVR by length of follow-up  
e: Stratified Analysis According to Follow-Up Length
3 years).         
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te [TVR
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DES in CTO April 27, 2010:1854–66Historically-controlled studies
De Felice et al            2.5  
Garcia-Garcia et al           4.9 
Ge et al            3.2  
Kandzari et al            0.8  
Kim et al            0.8  
Migliorini et al            0.9  
Wemer et al            1.0 
Subtotal  RR: 1.11 [0.52,2.35]       14.0  
Heterogeneity: I2 = 0%; (P = 0.47)  
Retrospective cohort studies 
HAN et al           72.1
La Spina et al             1.7 
Obunai et al            7.9  
Subtotal  RR: 0.83 [0.61,1.14]       81.7  
Heterogeneity:  I2 = 0%  (P = 0.95) 
Non•randomized controls studies  
Nakamura et al             Not estimable     
Subtotal  RR:  Not estimable             
Heterogeneity: Not applicable 
Randomized control trials 
Rahel and Suttorp et al         4.3 
Kelbæk et al                           Not estimable  
Subtotal  RR: 1.00 [0.26,3.89]      4.3   
Heterogeneity: Not applicable 
 
Overall RR: 0.87 [0.66,1.16]      100
Heterogeneity:   I2 = 0% ; (P = 0.73)
Historlcally-controlled studies  
De Felice et al  3.3  
Garcia-Garcia et al             6.8 
Ge et al              48.1
Kim et al                   Not estimable
Migliorini et al                     Not estimable
Wemer et al              3.0 
Subtotal  RR: 0.93 [0.49,1.78]         61.3
Heterogeneity: I2 = 0%; (P= 0.54)
Retrospective cohort studies
La Spina et al                                       5.3
Obunai et al            13.4 
Subtotal RR: 1.10 [0.35,3.44]         18.8
Heterogeneity: Not applicable 
Non•randomized controlled studies 
Nakamura et al            2.8 
Subtotal RR: 0.28 [0.01,5.40]         2.9 
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Figure 5 RR of Myocardial Infarction and Death Associated With DES and BMS Use
Forest plots for RR of myocardial infarction and death. Studies are stratified according to study design.
Same graph layout and color coding as in Figure 2. Abbreviations as in Figure 2.Non-randomized studies
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Figure 6 RR of Restenosis and Stent Reocclusion Associated With DES and BMS Use
Forest plots for RR of angiographic restenosis and stent reocclusion. Studies are stratified
according to study design. Same graph layout and color coding as in Figure 2. Abbreviations as in Figure 2.
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April 27, 2010:1854–66 DES in CTOngiographic follow-up, which has been shown repeatedly
o promote reinterventions (29). In support of the latter,
ngiographic follow-up was identified as a determinant of
VR heterogeneity in our meta-analysis.
Valuable angiographic information regarding DES per-
ormance was also gathered. Pooled data for the 2,144
atients with angiographic follow-up demonstrated a 75%
RR in restenosis rate. Of particular interest is the docu-
ented 73% RRR in stent reocclusion. Occlusive restenosis
onstitutes a complex and challenging subset of restenosis
rom the point of view of secondary percutaneous revascu-
arization, being fraught with substantial failure rates in the
hort and long term (30). In terms of NNT, 1 stent
eocclusion event was avoided by treating 15 CTO patients
ith a DES, a fact that might be kept in mind when
ssessing aspects such as the cost benefit of CTO recanali-
ation strategies.
A strong statistical trend toward a higher ST rate in the
ES group was documented. The absolute ST figures (4
nd 16 ST occurrences in BMS and DES groups, respec-
ively) expand those of the PRISON II randomized trial,
hich documented during a 3-year follow-up 5 ST episodes
n the DES and none in the BMS arms, respectively (20).
s pointed out previously, the endoluminal surface created
fter CTO recanalization constitutes a major challenge for
eointimal strut coverage with DES use, particularly when
ssociated with unfavorable features such as treatment of
ong segments, which are frequent in this context. Our
nalysis does not allow conclusions to be drawn about the
nfluence of DES type or antithrombotic treatment on the
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Figure 7 RR of ST Associated With DES and BMS Use
Forest plot of RRs of stent thrombosis (ST) rate. Studies are stratified according t
Academic Research Consortium (ARC) definitions. Same color coding as in Figureccurrence of ST. The 1.28% DES ST rate documented in aur analysis is virtually identical to that reported in other
ff-label indications (31), probably because in the context of
egressed collaterals after CTO recanalization, ST might
ause acute ischemia and myocardial necrosis. This would
e in contrast to the development of in-stent restenosis, in
hich the progressive luminal renarrowing associated with
eointimal growth may facilitate collateral reappearance.
uccessful CTO recanalization might thus induce, paradox-
cally, an increased risk of MI in those individuals with
egressed collaterals in whom ST develops. On the other
and, a higher prevalence of ST with DES use may reflect
he better results of DES in achieving long-term stent
atency because the more frequent occurrence stent reste-
osis and reocclusion in the BMS group may constitute a
ource of bias, which, unfortunately, cannot be adjusted for
ith the available data. A final remark is that because CTOs
re frequently located in vessels related to areas of previous
yocardial necrosis, asymptomatic ST or restenosis might
ave occurred after PCIs in arteries covering a territory with
imited myocardial viability. This, however, would be ex-
ected to affect the DES and BMS groups evenly.
tudy limitations. Our meta-analysis was not performed at
he patient level. It was largely based on NRCS, and
herefore careful assessment of quality and heterogeneity of
tudies, as well as sensitivity analysis, was performed to
vercome this limitation as much as possible. A propensity
core approach could not be used because this meta-analysis
as not performed at the patient level. In comparing our
ndings in CTOs with other lesion subsets, it must be kept
n mind that evidence on the latter will be based in more
     Not estimable 
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DES in CTO April 27, 2010:1854–66f very late ST (1 year from the index procedure) could not
e performed because only 4 studies had follow-up longer than
2 months. No specific data on when ST occurred were
eported (cumulative incidence of ST could therefore not be
alculated), and data on clopidogrel adherence were
navailable.
onclusions
his meta-analysis provides substantial evidence that DES
ignificantly decrease the occurrence of MACE, TVR, reste-
osis, and reocclusion without an increase in the incidence of
eath or MI. These results were sustained for more than 3
ears after the index PCI. Although a trend toward a higher
T rate was observed in DES-treated patients, further inves-
igation is necessary to confirm this finding.
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